This report investigates the impacts and development of Antibody-Drug Conjugate therapies within the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes within the market and how best to pivot to prioritize future changes in the market.
Report Scope
- This 53-page report gives important, expert insight you won’t find in any other source. 28 figures throughout the report illustrate major points and trends within the Antibody- Drug Conjugate market delving deep into forecasted sales and company pipelines. This report is required reading for:
- Investors that want to understand past trends impacting the Antibody- Drug Conjugate landscape as well as identifying companies to invest in
- Companies that are interested in entering the Antibody- Drug Conjugate landscape and where best to focus on
- Large pharma companies with investment groups or BD teams looking to see which companies lead the Antibody- Drug Conjugate landscape in the past and how they led
- Small and medium pharma who want to focus their Antibody- Drug Conjugate drug portfolio on future trends and are looking for partnership opportunities
Reasons to Buy
- Insights on the different types of Antibody- Drug Conjugate with current and novel forms
- Insights on past trends and changes that have informed the Antibody- Drug Conjugate market
- Insights on the current leading Antibody- Drug Conjugate drugs based on their Sales and Forecasts and other parameters
- Therapeutic and Indication insights into the Antibody- Drug Conjugate market
- Insights into the future opportunities for Antibody- Drug Conjugate and the companies leading in the market.
Table of Contents
1 Antibody-Drug Conjugate Introduction1.1 Key milestones timeline
1.2 Total market sales
1.3 Point-in-time counts
2 Antibody-Drug Conjugate: Previous Years in Review
2.1 ADCs by development stage
2.2 Approvals timeline
2.3 Historical sales
2.4 Deals trends
2.5 Patents trends
2.6 Review designation trends
3 Antibody-Drug Conjugate: Current Landscape
3.1 ADCs by development stage
3.2 Top indications
3.3 Top companies
4 Antibody-Drug Conjugate: Future Outlook
4.1 Forecast sales
4.2 Top companies
4.3 Upcoming launches
5 Key Findings
6 Appendix
6.1 Abbreviations
6.2 Methodology
6.3 About the Authors
6.4 About the Analyst
6.5 Contact the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pfizer
- Seagen
- F. Hoffmann-La Roche Ltd
- Roche Holding AG
- Daiichi-Sankyo Co Ltd
- Abbvie Inc
- Pfizer Inc
- Regeneron Pharmaceuticals Inc
- Gilead Sciences
- Novartis AG
- Bristol Myers Squibb Co
- Astrazeneca Plc
- Sanofi
- Biocytogen Pharmaceutical Co Ltd
- Hangzhou DAC Biotech Co Ltd
- LigaChem Biosciences Inc
- Innovent Biologics Inc
- Shanghai Affinity Biopharmaceutical Co Ltd
- LaNova Medicines Ltd
- Genmab AS
- Jiagsu Hengrui Pharmaceuticals Co Ltd
- Duality Biologics Co Ltd
- BioNTech SE
- Remegen Co Ltd
- CSPC Pharmaceutical Group Ltd
- Zai Lab
- Cytomx Therapeytics Inc
- GSK Plc
- Primelink Biotherapeutics Co Ltd
- Radiopharam Theranostics
- T-E Meds Inc
- Neok Bio Inc
- National Cancer Institute US
- Hutchmed China Ltd
